MarketResearchNest.com adds “Axillary Hyperhidrosis – Pipeline Review, H2 2017” new report to its research database. The report spread across in 52 pages with table and figures in it.
Latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis – Pipeline Review, H2 2017, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.
Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.
Enquiry for buying at: https://www.marketresearchnest.com/enquirybuy.php?reportid=260072
The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 4 and 1 respectively.
Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this report includes:
Allergan Plc, Brickell Biotech Inc, Dermira Inc, Dr. August Wolff GmbH & Co KG Arzneimittle, GlaxoSmithKline Plc, TheraVida Inc
Order a Premium Purchase Report Copy at : https://www.marketresearchnest.com/purchase.php?reportid=260072
Featured News & Press Releases
Mar 21, 2017: Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
Mar 17, 2017: Dermira to Present Data on Glycopyrronium Tosylate Clinical Program at Annual Maui Derm Meeting
Mar 03, 2017: Dermira Presents New Data in Primary Axillary Hyperhidrosis at American Academy of Dermatology 2017 Annual Meeting
Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis
Feb 27, 2017: Dermira Data from DRM04 Clinical Program to Be Presented at American Academy of Dermatology Annual Meeting
Oct 13, 2016: Dermira to Present Data from DRM04 Clinical Program at Fall Clinical Dermatology Conference
Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis
Oct 01, 2016: Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
Sep 28, 2016: Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
Jun 01, 2016: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis
Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating
Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
Jan 07, 2016: Dermira Provides DRM04 Development Program Update
Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis
Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquiry for Discount at: https://www.marketresearchnest.com/requestdiscount.php?reportid=260072
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain